With big pharma leaning on external pipelines, the company sees opportunity in de-risked, high-impact assets with clear clinical endpoints
On the generics and biosimilars front, the combined business is expected to benefit from Sun’s portfolio of more than 550 approved ANDAs across multiple dosage forms
The move reinforces Croda’s push to fuel growth through high-impact innovation across its Consumer Care portfolio
Solvents made from renewable feedstocks help reduce reliance on fossil-fuel-based materials
These tests deliver results in 10–15 minutes at a cost of Rs 100–Rs 150, compared to conventional diagnostics which cost up to Rs 15,000
In his new role, Curtis will lead the formulation and execution of the company’s global technical strategy
The innovation is particularly suited for bone and cartilage repair
Postdoctoral fellowship aims to build skilled talent pool in biotechnology and life sciences
CDSCO-approved therapy enters India’s fast-growing post-patent GLP-1 market with fully integrated API, formulation and pen manufacturing
The 12-month alpha-testing phase will bring together ZEISS R&D, three academic collaborators, and three pharmaceutical industry partners
Subscribe To Our Newsletter & Stay Updated
